Eiji Aoyama, Ph.D.

Director, Development Planning


Dr. Aoyama, who holds a PhD in Pharmaceutical Science, has more than 25 years of global drug development experience and is an expert in Non-clinical Development and Clinical Pharmacology (transitioning from pre-clinical to clinical phase). He gained his working experience at Takeda, and most recently at Eli Lilly in Japan, where he was a Team Leader of Eli Lilly’s Japan PKPD Group.

Dr. Aoyama’s experience covers a wide range of therapeutic areas including Diabetes, Cardiovascular, CNS, Oncology, and Immunology, with an in-depth understanding of the Japanese regulatory environment to support the design and implementation of required studies for regulatory approval in Japan.

Ready for regulatory clarity? Contact us.